Overview

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Status:
Not yet recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate

Phase:

Phase 2

Details

Lead Sponsor:

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Treatments:

Apatinib